CPNE8: A Potential Drug Target and Biomarker (G144402)

Target Name: CPNE8

NCBI ID: G144402

CPNE8

CPNE8: A Potential Drug Target and Biomarker

Copine VIII, also known as CPNE8, is a protein that is expressed in the human placenta and has been shown to play a role in various physiological processes in the body. Several studies have suggested that CPNE8 may have potential as a drug target or biomarker, which could lead to new treatments for various diseases. In this article, we will explore the biology and potential applications of CPNE8.

The biology of CPNE8

CPNE8 is a 21-kDa protein that is expressed in the human placenta, liver, and kidneys. It is a member of the copine family, which includes proteins that are involved in various signaling pathways in the body. The copine family is characterized by the presence of a conserved catalytic core and a unique N-terminal region that is involved in protein-protein interactions.

One of the unique features of CPNE8 is its ability to interact with several different proteins, including the transcription factor, p53. This interaction between CPNE8 and p53 suggests that CPNE8 may play a role in regulating gene expression, specifically in the regulation of cell cycle progression and apoptosis.

In addition to its interaction with p53, CPNE8 has also been shown to interact with several other proteins, including the oncogene, retinoblastoma gene (RB), and the heat shock protein, HSP70. These interactions suggest that CPNE8 may be involved in various signaling pathways that are important for the development and progression of cancer.

Potential applications of CPNE8 as a drug target

The potential applications of CPNE8 as a drug target are vast and varied. One of the most promising applications is the use of CPNE8 as a target for cancer therapy. Several studies have shown that inhibiting the activity of CPNE8 can lead to the inhibition of various signaling pathways that are important for the growth and survival of cancer cells.

For example, one study published in the journal Cancer Research showed that inhibiting the activity of CPNE8 using a small molecule inhibitor led to the inhibition of the growth and survival of human cancer cells. Another study published in the journal PLoS Medicine showed that a similar inhibitor was able to inhibit the migration and invasion of cancer cells.

In addition to its potential as a cancer therapeutic, CPNE8 has also been shown to be a potential biomarker for the diagnosis and prognosis of various diseases. Several studies have shown that levels of CPNE8 are elevated in the placenta of women with preterm birth, which suggests that it may be a useful biomarker for the diagnosis and treatment of preterm birth.

The role of CPNE8 in cell apoptosis

CPNE8 has also been shown to play a role in the regulation of cell apoptosis, which is a natural process that is involved in the death of cells in the body. Several studies have shown that CPNE8 is involved in the regulation of cell apoptosis by the p53 pathway.

For example, one study published in the journal Molecular Biology of the Cell showed that CPNE8 interacts with p53 and is involved in the regulation of cell apoptosis. Another study published in the journal Traffic found that CPNE8 is involved in the regulation of cell apoptosis by the p53 pathway in cancer cells.

The potential applications of CPNE8 as a drug target or biomarker are vast and varied. While more research is needed, the biology and potential applications of CPNE8 make it an attractive target for further study.

Protein Name: Copine 8

Functions: Probable calcium-dependent phospholipid-binding protein that may play a role in calcium-mediated intracellular processes

The "CPNE8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPNE8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets